Preston Klassen - Jan 30, 2025 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
President & Head of R & D, Director
Signature
Christopher Aker, Attorney in Fact
Stock symbol
RGLS
Transactions as of
Jan 30, 2025
Transactions value $
$0
Form type
4
Date filed
1/31/2025, 05:00 PM
Previous filing
Jan 15, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +675K $0.00 675K Jan 30, 2025 Common Stock 675K $1.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option commenced vesting on January 1, 2025 and will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.